Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | PRKX | P51817 | 1/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | STK3 | Q13188 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7646 | 0.84 | KDM4E (0.46) | PARP1 | |
| SCHEMBL3726213 | 0.83 | CHEK1 (0.49) | PARP1PIM1PARP2PLK4MAPK13 | |
| SCHEMBL1933246 | 0.83 | PARP1 (0.69) | PARP1PIM1PARP2PLK4MAPK13 | |
| SCHEMBL20479886 | 0.81 | PARP1 (0.46) | PARP1PIM1PARP2PLK4MAPK13 | |
| SCHEMBL3137529 | 0.81 | HRH4 (0.58) | PARP1 | |
| SCHEMBL27720114 | 0.80 | KDM4E (0.57) | PARP1PIM1PARP2PLK4MAPK13 | |
| SCHEMBL20479692 | 0.79 | PARP1 (0.51) | PARP1PARP2 | |
| SCHEMBL9588827 | 0.78 | PARP1 (0.47) | PARP1PIM1PARP2PLK4MAPK13 | |
| SCHEMBL8598655 | 0.76 | PKN1 (0.53) | PARP1PARP2PKN1PKN2 | |
| SCHEMBL2127145 | 0.75 | PKN1 (0.59) | PARP1PARP2PKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590333-A4 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS INC (KR) | 2008-04-30 | — | — | EP | disclosed |
| EP-1590333-A4 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS INC (KR) | 2008-04-30 | — | — | EP | disclosed |
| US-7179832-B2 | Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-7179832-B2 | Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2006-04-13 | — | — | US | disclosed |
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2006-04-13 | — | — | US | disclosed |
| EP-1590333-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | Crystalgenomics, Inc. (KR) | 2005-11-02 | — | — | EP | disclosed |
| EP-1590333-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | Crystalgenomics, Inc. (KR) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065370-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS, INC. (KR) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004065370-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS, INC. (KR) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | GSK3B, GSK3A, GYS2 | PARP1 2518/4885PIM1 1570/4885PARP2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.